Status:
UNKNOWN
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
Lead Sponsor:
University of Kansas Medical Center
Collaborating Sponsors:
Gilead Sciences
Conditions:
Fatty Liver
NAFLD
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: During the hepatology evaluation, vibration-controlled transient elastography (VCTE) is often used as a clinical decision aid to target high-risk patients for liver biopsy. The enhanced li...
Eligibility Criteria
Inclusion
- Patients from hepatology clinic undergoing new evaluation for NAFLD.
Exclusion
- Patients with liver biopsy within the last five years or decompensated cirrhosis were excluded. Patients known to have other liver diseases were also excluded. Patients consuming \> 14 drinks in the past 6 months were excluded. Patients may be subsequently found to have positive viral or autoimmune serologies after enrollment because the serology result is typically not available at the time of enrollment. These patients will be excluded from the analysis.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05370053
Start Date
September 1 2020
End Date
December 1 2022
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160